Linked Life Data

18221046

Source:http://linkedlifedata.com/resource/pubmed/id/18221046

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2008-1-28
pubmed:abstractText
The cyclin dependent kinases, Cdks, are potential targets for new anticancer therapy. Dysregulation of the cell cycle is common during tumorigenesis, and inhibition of certain Cdks has been shown to inhibit tumor cell growth, induce apoptosis and cause tumor regressions in animal models. This review discusses the rationale for inhibiting Cdks as an approach to cancer therapy and the status of Cdk inhibitors in clinical trials. Compounds resulting from a patent literature search from 2003 to July, 2005 are discussed.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1574-8928
pubmed:author
pubmed:issnType
Print
pubmed:volume
1
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
357-67
pubmed:dateRevised
2011-11-10
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Inhibition of cyclin-dependent kinases - a review of the recent patent literature.
pubmed:affiliation
Schering-Plough Research Institute, Department of Tumor Biology, 2015 Galloping Hill Road, Kenilworth, NJ 07033-1300, USA.
pubmed:publicationType
Journal Article, Review